Form 4: Corbus Director Exercises Options, Sells Shares

Corbus Pharmaceuticals Director Anne Altmeyer exercised stock options and subsequently sold an equal number of common shares, as disclosed in a recent Form 4 filing.

Summary

• Anne Altmeyer, a Director of Corbus Pharmaceuticals Holdings, Inc. (CRBP), reported transactions on October 20, 2025.
• Altmeyer exercised 1,060 stock options at an exercise price of $4.80 per share.
• Concurrently, Altmeyer sold 1,060 shares of common stock at a price of $20.50 per share.
• The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on November 14, 2024.
• Following these transactions, Altmeyer beneficially owns 6,191 shares of common stock.
• The beneficial ownership includes 4,800 unvested Restricted Stock Units (RSUs) granted on May 30, 2025, which are scheduled to vest 100% on May 30, 2026.
• The exercised options were fully vested and granted under the issuer's 2014 Equity Compensation Plan, with an expiration date of September 26, 2032.

Sentiment

Score: 5

Explanation: The filing reports a routine insider transaction involving the exercise of options and subsequent sale of shares under a pre-arranged plan. This is a neutral event, common for executives managing their equity compensation, and does not inherently indicate positive or negative sentiment about the company's prospects.

Positives

• The director realized a significant profit from the option exercise and subsequent sale, with shares sold at $20.50 after being acquired at $4.80.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan, indicating a planned, rather than opportunistic, sale.

Negatives

• An insider selling shares, even under a 10b5-1 plan, could be perceived by some investors as a lack of confidence, though this is a routine compensation-related transaction.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing reports a routine insider transaction related to executive compensation, which is common across all industries, particularly in biotechnology where equity compensation is a significant component of remuneration. It does not provide specific insights into broader industry trends or competitive positioning.

Related Party Transactions

• The reported transactions involve a director of Corbus Pharmaceuticals Holdings, Inc., Anne Altmeyer, exercising stock options and selling common stock, which constitutes a related party transaction.

Stakeholder Impact

• Shareholders: The transaction is a routine insider sale under a 10b5-1 plan, which typically has minimal direct impact on shareholder value or perception, unless the scale is unusually large or frequent.
• Employees: No direct impact on employees is indicated by this filing.

Next Steps

• 4,800 unvested RSUs held by the reporting person are scheduled to vest 100% on May 30, 2026.

Key Dates

Keywords

Corbus Pharmaceuticals, CRBP, Form 4, Insider Transaction, Stock Options, Share Sale, Anne Altmeyer, Director, 10b5-1 Plan